See the DrugPatentWatch profile for yervoy

Yervoy Cost Reduction: How Long Does it Last?

Understanding the Cost Burden of Cancer Treatment

Cancer treatment can be a significant financial burden for patients, with costs ranging from tens of thousands to hundreds of thousands of dollars per year. One of the most effective treatments for melanoma, Yervoy (ipilimumab), has been a game-changer in the fight against this deadly disease. However, its high cost has made it inaccessible to many patients. In this article, we'll explore the cost reduction strategies for Yervoy and how long they may last.

The High Cost of Yervoy

Yervoy, developed by Bristol-Myers Squibb, is a monoclonal antibody that works by boosting the immune system's ability to fight cancer cells. It has been shown to improve overall survival rates and response rates in patients with advanced melanoma. However, its high cost has made it a challenge for many patients to access.

Cost Reduction Strategies

To make Yervoy more affordable, several cost reduction strategies have been implemented:

Generic Competition

The patent for Yervoy expired in 2020, allowing generic versions of the drug to enter the market. Generic competition can lead to significant price reductions, making the drug more accessible to patients.

Biosimilar Development

Biosimilars are biologic medicines that are highly similar to existing biologics, such as Yervoy. Biosimilar development can lead to further cost reductions and increased competition in the market.

Pricing Negotiations

Pharmaceutical companies, like Bristol-Myers Squibb, are negotiating with payers and governments to reduce the cost of Yervoy. These negotiations can result in lower prices for patients.

Patient Assistance Programs

Patient assistance programs (PAPs) are designed to help patients access medications at a reduced cost. PAPs for Yervoy can provide financial assistance to eligible patients.

Value-Based Pricing

Value-based pricing is a pricing model that ties the cost of a medication to its clinical value. This model can lead to lower prices for patients if the medication is deemed to be highly effective.

How Long Will the Cost Reduction Last?

The cost reduction strategies mentioned above can lead to significant savings for patients. However, the duration of these savings is uncertain.

Generic Competition

Generic competition can lead to significant price reductions, but the duration of these savings is uncertain. As more generic versions of Yervoy enter the market, prices may continue to fall.

Biosimilar Development

Biosimilar development can lead to further cost reductions, but the timeline for biosimilar approval is uncertain. Biosimilars may take several years to develop and gain approval, during which time prices may remain high.

Pricing Negotiations

Pricing negotiations can lead to temporary price reductions, but these reductions may not be sustainable in the long term. Pharmaceutical companies may increase prices in the future to maintain profitability.

Patient Assistance Programs

PAPs can provide financial assistance to eligible patients, but these programs may have limited funding and may not be available to all patients.

Value-Based Pricing

Value-based pricing can lead to lower prices for patients if the medication is deemed to be highly effective. However, the effectiveness of Yervoy may vary depending on individual patient responses, and the pricing model may not be sustainable in the long term.

Conclusion

Yervoy is a highly effective treatment for melanoma, but its high cost has made it inaccessible to many patients. Several cost reduction strategies have been implemented, including generic competition, biosimilar development, pricing negotiations, patient assistance programs, and value-based pricing. While these strategies can lead to significant savings for patients, the duration of these savings is uncertain. Patients and healthcare providers must continue to advocate for affordable access to Yervoy and other life-saving medications.

Key Takeaways

* Yervoy is a highly effective treatment for melanoma, but its high cost has made it inaccessible to many patients.
* Several cost reduction strategies have been implemented, including generic competition, biosimilar development, pricing negotiations, patient assistance programs, and value-based pricing.
* The duration of these savings is uncertain and may vary depending on individual patient responses and market conditions.
* Patients and healthcare providers must continue to advocate for affordable access to Yervoy and other life-saving medications.

FAQs

1. How much does Yervoy cost?

Yervoy costs around $12,000 per month, making it a significant financial burden for patients.

2. What are the cost reduction strategies for Yervoy?

Several cost reduction strategies have been implemented, including generic competition, biosimilar development, pricing negotiations, patient assistance programs, and value-based pricing.

3. How long will the cost reduction last?

The duration of the cost reduction is uncertain and may vary depending on individual patient responses and market conditions.

4. What is the patent status of Yervoy?

The patent for Yervoy expired in 2020, allowing generic versions of the drug to enter the market.

5. What is a biosimilar?

A biosimilar is a biologic medicine that is highly similar to an existing biologic, such as Yervoy. Biosimilars can lead to further cost reductions and increased competition in the market.

Cited Sources

1. DrugPatentWatch.com. (2020). Yervoy (Ipilimumab) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration/yervoy-ipilimumab>
2. Bristol-Myers Squibb. (2020). Yervoy (Ipilimumab) Prescribing Information. Retrieved from <https://packageinserts.bms.com/pi/pi_yervoy.pdf>
3. National Cancer Institute. (2020). Ipilimumab. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/ipilimumab>
4. Pharmaceutical Research and Manufacturers of America. (2020). Biosimilars. Retrieved from <https://www.phrma.org/-/media/PhRMA/Website/PhRMA-Org/PhRMA-Website/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA-Content/PhRMA